Background Inflammation serves as our body's immune response to combat infections,
pathogens, viruses, and external stimuli. Inflammation can be classified into two types: acute …

Background Dietary management of patients with inflammatory bowel disease (IBD)
involves more than defining a therapeutic diet. The profusion of 'expert advice'is not …

Background The optimal dosing strategy for infliximab in steroid-refractory acute severe
ulcerative colitis (ASUC) is unknown. We compared intensified and standard dose infliximab …

Inflammatory bowel disease (IBD) is a chronic and relapsing immune‐mediated disease of
the gastrointestinal tract with a gradually increasing global incidence and prevalence. A …

Background There are a plethora of therapeutic options for the management of inflammatory
bowel disease (IBD). Despite this, clinical outcomes with standard dosing often fall short of …

The introduction of tumor necrosis factor inhibitors has led to a paradigm shift in the
management of inflammatory bowel disease (IBD). The subsequent introduction of both anti …

Small molecule Janus kinase (JAK) inhibitors have revolutionized the management of
ulcerative colitis (UC) and Crohn's disease (CD) through their low immunogenicity, safety …

ABSTRACT Introduction Therapeutic Drug Monitoring (TDM) has an important role in the
management of inflammatory bowel disease (IBD) patients on infliximab (IFX) or …

The treatment goal for patients with Crohn's disease (CD) has traditionally been aimed at
symptomatic steroid-free clinical remission [1]. Mucosal healing, endoscopic healing, and …

Several therapeutic advances have been achieved over the past two decades for
inflammatory bowel disease (IBD). The expanding therapeutic armamentarium and the …